Followers | 837 |
Posts | 120354 |
Boards Moderated | 18 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Wednesday, April 21, 2004 11:30:02 AM
According to the company, it will take a year to enroll 150-200 patients in the confirmatory trial once the trial actually gets underway. Then the patients will have to be followed for at least another year (and perhaps longer) to determine the survival benefit. Add time for data analysis and the FDA review and we are talking about a minimum of three years before RIGS could be approved for marketing with a survival indication.
Regarding the so-called “diagnostic approval” mentioned in the CC, this is merely a hope on NEOP’s part; the FDA has not agreed to entertain approval of RIGS without a survival benefit, although they might still decide to do so.
Moreover, I can’t see RIGS attaining much commercial traction without a survival indication. Several posters have stated that they would surely want RIGS to be used if they had colorectal cancer. I agree with this completely but, emotions aside, you have to look at things from the surgeon’s perspective too.
Surgeons are busy and time is money. Why would a surgeon want to mess with a cumbersome tool involving radioactive materials without an FDA label that going to all this trouble will provide a bona fide survival benefit to the patient?
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent NAVB News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/21/2023 08:32:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 11:26:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 04:49:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:55:52 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 10/23/2023 05:56:24 PM
- Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock • Business Wire • 10/06/2023 01:01:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/05/2023 08:21:49 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/15/2023 07:42:35 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/11/2023 04:15:30 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM